<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89010">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01865552</url>
  </required_header>
  <id_info>
    <org_study_id>SB4-G11-NHV</org_study_id>
    <secondary_id>2012-004371-39</secondary_id>
    <nct_id>NCT01865552</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB4 in Healthy Male Subjects</brief_title>
  <official_title>A Randomised, Single-blind, Three-part, Two-period, Two-sequence, Single-dose, Cross-over Study to Compare the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Three Formulations of Etanercept (SB4, EU Sourced Enbrel® and US Sourced Enbrel®) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Bioepis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Bioepis Co., Ltd.</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetics, safety and immunogenicity of
      SB4 and Enbrel (EU sourced Enbrel and US sourced Enbrel) in healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Part A: Comparison between SB4 and EU sourced Enbrel

        -  Part B: Comparison between SB4 and US sourced Enbrel

        -  Part C: Comparison between EU sourced Enbrel and US sourced Enbrel
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)</study_design>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to infinity (AUCinf)</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum serum concentration (Cmax)</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero to the last quantifiable concentration (AUClast)</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SB4 and EU sourced Enbrel in Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB4 followed by EU sourced Enbrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU sourced Enbrel and SB4 in Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EU sourced Enbrel followed by SB4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB4 and US sourced Enbrel in Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB4 followed by US sourced Enbrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US sourced Enbrel and SB4 in Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>US sourced Enbrel followed by SB4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU and US sourced Enbrel in Part C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>EU sourced Enbrel followed by US sourced Enbrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US and EU sourced Enbrel in Part C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>US sourced Enbrel followed by EU sourced Enbrel</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB4</intervention_name>
    <description>SC administration</description>
    <arm_group_label>SB4 and EU sourced Enbrel in Part A</arm_group_label>
    <arm_group_label>EU sourced Enbrel and SB4 in Part A</arm_group_label>
    <arm_group_label>SB4 and US sourced Enbrel in Part B</arm_group_label>
    <arm_group_label>US sourced Enbrel and SB4 in Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EU sourced Enbrel</intervention_name>
    <description>SC administration</description>
    <arm_group_label>SB4 and EU sourced Enbrel in Part A</arm_group_label>
    <arm_group_label>EU sourced Enbrel and SB4 in Part A</arm_group_label>
    <arm_group_label>EU and US sourced Enbrel in Part C</arm_group_label>
    <arm_group_label>US and EU sourced Enbrel in Part C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>US sourced Enbrel</intervention_name>
    <description>SC administration</description>
    <arm_group_label>SB4 and US sourced Enbrel in Part B</arm_group_label>
    <arm_group_label>US sourced Enbrel and SB4 in Part B</arm_group_label>
    <arm_group_label>EU and US sourced Enbrel in Part C</arm_group_label>
    <arm_group_label>US and EU sourced Enbrel in Part C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects

          -  Have a body weight between 60 and 94.9 kg and a body mass index between 20.0 and 29.9
             kg/m², inclusive.

        Exclusion Criteria:

          -  history and/or current presence of clinical significant atopic allergy,
             hypersensitivity or allergic reactions, also including known or suspected clinically
             relevant drug hypersensitivity to any components of the test and reference IP
             formulation or comparable drugs.

          -  active or latent Tuberculosis or who have a history of TB.

          -  history of invasive systemic fungal infections or other opportunistic infections

          -  systemic or local infection, a known risk for developing sepsis and/or known active
             inflammatory process

          -  serious infection associated with hospitalisation and/or which required intravenous
             antibiotics

          -  history of and/or current cardiac disease

          -  have received live vaccine(s) within 30 days prior to Screening or who will require
             live vaccine(s) between Screening and the final study visit.

          -  Intake medication with a half-life &gt; 24 h within 1 month or 10 half-lives of the
             medication prior to the first administration of IP.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainard Fuhr, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel International GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International GmbH</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 10, 2013</lastchanged_date>
  <firstreceived_date>May 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>TNFR-Fc fusion protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
